DeepMed Research

Mitsubishi Tanabe Pharma America, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 2015-01-01

Employees: 101

Market Cap: -

Website: http://www.mt-pharma-america.com

Clinical Trials

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Phase 2

Completed

Conditions: Diffuse Cutaneous Systemic Sclerosis

Interventions: Drug: MT-7117
Drug: Placebo

First Posted Date: 2020-06-19

Last Posted Date: 2025-01-15

Lead Sponsor: Mitsubishi Tanabe Pharma America Inc.

Target Recruit Count: 76

Registration Number: NCT04440592

Locations: 🇵🇱
Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland
🇵🇱
Malopolskie Centrum Kliniczne, Krakow, Poland
🇩🇪
University Hospital Of Tuebingen, Tuebingen, Baden-Wuettemberg, Germany

and more 31 locations

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

Phase 3

Completed

Conditions: EPP
XLP

Interventions: Drug: MT-7117 High Dose
Drug: Placebo
Drug: MT-7117 Low Dose

First Posted Date: 2020-05-26

Last Posted Date: 2025-03-21

Lead Sponsor: Mitsubishi Tanabe Pharma America Inc.

Target Recruit Count: 184

Registration Number: NCT04402489

Locations: 🇺🇸
Remington-Davis Clinical Research, Columbus, Ohio, United States
🇺🇸
The University of Texas Medical Branch (UTMB), Galveston, Texas, United States
🇬🇧
University of Manchester, Salford, Manchester, United Kingdom

and more 28 locations

Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

Active, not recruiting

Conditions: ALS
Amyotrophic Lateral Sclerosis

Interventions: Drug: Edaravone (Radicava®/Radicava ORS®)

First Posted Date: 2020-02-06

Last Posted Date: 2023-08-24

Lead Sponsor: Mitsubishi Tanabe Pharma America Inc.

Target Recruit Count: 300

Registration Number: NCT04259255

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇨🇦
SunnyBrook Research Institute, Toronto, Ontario, Canada
🇺🇸
Jefferson Weinberg ALS Center, Philadelphia, Pennsylvania, United States

and more 17 locations

Safety Study of Oral Edaravone Administered in Subjects With ALS

Phase 3

Completed

Conditions: ALS

Interventions: Drug: MT-1186

First Posted Date: 2019-11-18

Last Posted Date: 2023-05-15

Lead Sponsor: Mitsubishi Tanabe Pharma America Inc.

Target Recruit Count: 185

Registration Number: NCT04165824

Locations: 🇺🇸
Neurology Associates, P.C - Lincoln, Lincoln, Nebraska, United States
🇺🇸
Texas Neurology, PA, Dallas, Texas, United States
🇺🇸
Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States

and more 50 locations

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Phase 1

Completed

Conditions: Mild and Moderate Hepatic Impairment

Interventions: Drug: MT-7117

First Posted Date: 2019-10-04

Last Posted Date: 2023-05-15

Lead Sponsor: Mitsubishi Tanabe Pharma America Inc.

Target Recruit Count: 23

Registration Number: NCT04116476

Locations: 🇺🇸
University of Miami Clinical Pharmacology Unit, Miami, Florida, United States

Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury

Phase 1

Completed

Conditions: Spinal Cord Injury

Interventions: Biological: MT-3921 Low dose

First Posted Date: 2019-09-20

Last Posted Date: 2023-05-15

Lead Sponsor: Mitsubishi Tanabe Pharma America Inc.

Target Recruit Count: 3

Registration Number: NCT04096950

Locations: 🇺🇸
Vidant Medical Center, Greenville, North Carolina, United States
🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
Carle Foundation Hospital, Urbana, Illinois, United States

and more 10 locations

Safety and Efficacy Study of MT-2990 in Women With Endometriosis

Phase 2

Completed

Conditions: Endometrial Related Pain

Interventions: Drug: Placebo
Drug: MT-2990

First Posted Date: 2019-02-15

Last Posted Date: 2024-07-10

Lead Sponsor: Mitsubishi Tanabe Pharma America Inc.

Target Recruit Count: 76

Registration Number: NCT03840993

Locations: 🇺🇸
Medi-Sense, Atlanta, Georgia, United States
🇺🇸
Drug Studies America - Marietta, Marietta, Georgia, United States
🇺🇸
Clinical Research Prime, Idaho Falls, Idaho, United States

and more 47 locations

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: MT-6345
Drug: MT-6345 Placebo

First Posted Date: 2019-01-18

Last Posted Date: 2023-05-15

Lead Sponsor: Mitsubishi Tanabe Pharma America Inc.

Target Recruit Count: 52

Registration Number: NCT03809039

Locations: 🇬🇧
Investigational center, City Name, United Kingdom

Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: MT-7117
Drug: PPI
Dietary Supplement: Acidic beverage

First Posted Date: 2018-09-27

Last Posted Date: 2023-05-15

Lead Sponsor: Mitsubishi Tanabe Pharma America Inc.

Target Recruit Count: 50

Registration Number: NCT03688022

Locations: 🇩🇪
Investigational Centre(s), Germany, Germany

Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms

Phase 2

Completed

Conditions: Vasomotor Symptoms (VMS)

Interventions: Drug: MT-8554

First Posted Date: 2018-05-30

Last Posted Date: 2023-05-15

Lead Sponsor: Mitsubishi Tanabe Pharma America Inc.

Target Recruit Count: 190

Registration Number: NCT03541200

Locations: 🇺🇸
Research Site, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy